Treatment for Cancer of Pancreas

Waitlist Available · 18+ · All Sexes · Detroit, MI

This study is evaluating whether a new treatment strategy is safe and effective.

See full description

About the trial for Cancer of Pancreas

Eligible Conditions
Pancreas Neoplasm Malignant Resectable · Pancreatic Neoplasms · Neoplasms

Treatment Groups

This trial involves a single treatment. Treatment is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.

Main TreatmentA portion of participants receive this new treatment to see if it outperforms the control.
Control TreatmentAnother portion of participants receive the standard treatment to act as a baseline.


This trial is for patients born any sex aged 18 and older. There are 8 eligibility criteria to participate in this trial as listed below.

Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:
This text is discussing how a CT scan can be used to assess whether or not someone has a disease. show original
The person has an Eastern Cooperative Oncology Group (ECOG) performance status of 1 or less, which means they are able to carry out all self-care activities and work. show original
The following laboratory data is required for the study protocol show original
Ability to understand and the willingness to sign a written informed consent document
that is metastatic, locally advanced, or unresectable to be eligible for study treatment show original
-1 Patients must have confirmed surgically resectable or borderline resectable disease at study entry, staged at T1-3, NO-1 and MO-1. show original
Age >/= 18years
patient The investigator believes that the patient has a life expectancy of more than six months, excluding those with pancreatic cancer. show original
View All
Odds of Eligibility
Be sure to apply to 2-3 other trials, as you have a low likelihood of qualifying for this one.Apply To This Trial
Similar Trials

Approximate Timelines

Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: 6 weeks
Screening: ~3 weeks
Treatment: Varies
Reporting: 6 weeks
This trial has approximate timelines as follows: 3 weeks for initial screening, variable treatment timelines, and reporting: 6 weeks.
View detailed reporting requirements
Trial Expert
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like

Measurement Requirements

This trial is evaluating whether Treatment will improve 1 primary outcome in patients with Cancer of Pancreas. Measurement will happen over the course of 6 weeks.

Primary Tumor Response
Diagnostic imaging and RECIST criteria will be used to evaluate and record response of the primary tumor

Who is running the study

Principal Investigator
G. K.
Gazala Khan, MD
Henry Ford Health System

Patient Q & A Section

Ask a question about the study

Other questions from users

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any geographic restrictions to consider when applying for this trial?

Patients from any state can participate in this trial, so long as they are able to attend all treatment sessions.

Will my insurance cover participating in this trial?

In order to understand how insurance coverage works for this trial, you will need to contact the study coordinator.

See if you qualify for this trial
Get access to this novel treatment for Cancer of Pancreas by sharing your contact details with the study coordinator.